Ximelagatran and melagatran vs. low-molecular-weight heparin in major orthopedic surgery: relationship between efficacy and safety and timing of initial administration.
Zufferey
P
P
Laporte
S
S
Molliex
S
S
Auboyer
C
C
Mismetti
P
P
D000925:Anticoagulants / Q000494:pharmacology; D019644:Arthroplasty, Replacement, Hip; D019645:Arthroplasty, Replacement, Knee; D001384:Azetidines / Q000008:administration & dosage*; D001596:Benzylamines; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D005998:Glycine / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology*; D006801:Humans; D015201:Meta-Analysis as Topic; D009985:Orthopedics / Q000379:methods*; D011897:Random Allocation; D012044:Regression Analysis; D012306:Risk; D012307:Risk Factors; D013917:Thrombin / Q000037:antagonists & inhibitors; D013923:Thromboembolism / Q000517:prevention & control
D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; C109573:melagatran; C426686:ximelagatran; D013917:Thrombin; D005998:Glycine